Saturday 17 October 2026
Export ACRS’s income statement to Excel — free account
Aclaris Therapeutics, Inc.
ACRS Healthcare Biotechnology
Aclaris Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.8 million, down 58.2% from fiscal 2024. In the quarter to June 2026, revenue fell 8.33%, EPS fell 15.4% and free cash flow fell 98.8%, each against the same quarter a year earlier.
3.28
0.21
−6.02%
Follow ACRS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
91.87 | 57.73 | 47.14 | 14.80 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(38.04) | (26.62) | (28.10) | (21.31) | |
P/B ratio |
6.06 | 3.36 | 3.58 | 1.94 | |
Price to Tangible BV |
6.42 | 3.53 | 3.84 | 2.06 | |
EV/Sales |
82.04 | 46.41 | 36.92 | 9.39 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(10.86) | (7.44) | (6.13) | (3.44) | |
EV/FCF |
(10.84) | (7.43) | (6.12) | (3.44) | |
Quick Ratio |
3.46 | 4.03 | 3.36 | 3.92 | |
Current Ratio |
3.46 | 4.03 | 3.36 | 3.92 | |
Net Debt/EBITDA |
3.79 | 4.77 | 4.01 | 5.63 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.04 | 0.04 | 0.04 | 0.09 | |
Operating CF/Net income |
0.92 | 0.92 | 0.66 | 0.75 | |
Capex/Depreciation |
(0.54) | (0.13) | (0.24) | (0.21) | |
Research and Development Expense of Revenue |
1,109.02% | 784.42% | 1,280.62% | 394.91% | |
Selling, General and Administrative Expense of Revenue |
371.27% | 337.83% | 430.58% | 147.65% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
164.03% | 160.22% | 225.95% | 86.69% | |
Graham Net Nets |
0.06 | 0.11 | 0.11 | 0.19 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(10.96%) | (14.93%) | (17.61%) | (72.63%) | |
Free Cash Flow Yield |
(8.23%) | (10.82%) | (12.80%) | (18.46%) | |
Revenue per Share |
0.01 | 0.02 | 0.01 | 0.03 | |
Operating CF per Share |
(0.14) | (0.14) | (0.11) | (0.09) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.14) | (0.14) | (0.11) | (0.09) | |
Cash per Share |
0.64 | 0.82 | 0.74 | 0.78 | |
Shareholders Equity per Share |
0.87 | 1.12 | 0.84 | 0.98 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.87 | 1.12 | 0.84 | 0.98 | |
Free Cash Flow |
(19.90) | (18.16) | (13.15) | (10.95) | |
Working Capital |
69.52 | 82.86 | 67.67 | 74.96 | |
Capital Expenditures |
(0.06) | (0.01) | (0.02) | (0.02) | |
Net Current Asset Value |
42.65 | 55.16 | 38.94 | 45.16 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.01 | 0.02 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
3.20 | 2.53 | 8.96 | 2.51 | |
Average Payables |
12.16 | 10.54 | 8.92 | 8.42 | |
Average Assets |
184.42 | 198.41 | 190.39 | 178.96 | |
Average Common Equity |
128.16 | 143.86 | 129.32 | 125.13 |
Columns are period end dates